Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis,psoriatic arthritis,and ankylosing spondylitis

Abstract

Background

Golimumab (GLM) has shown its efficacy and safety in various clinical trials. We aimed to assess the effect of GLM on socio economic and health economic parameters in daily clinical practice.     

Evidence‐based recommendations for the monitoring and treatment of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology

Aim: To develop a set of Australian recommendations for the monitoring and treatment of ankylosing spondylitis (AS) through systematic literature review combined with the opinion of practicing rheumatologists. Methods: A set of eight questions, four in each domain of monitoring and treatment, were formulated by voting and the Delphi method. The results of a systematic literature review addressing each question were presented to the 23 participants of the Australian 3E meeting. All participants were clinical rheumatologists experienced in the daily management of AS. Results: After three rounds of breakout sessions to discuss the findings of the literature review, a set of recommendations was finalized after discussion and voting. The category of evidence and strength of recommendation were determined for each proposal. The level of agreement among participants was excellent (mean 84%, range 64–100%). Conclusions: The 12 recommendations developed from evidence and expert opinion provide guidance for the daily management of AS patients. For most recommendations, we found a paucity of supportive evidence in the literature highlighting the need for additional clinical studies.     

The efficacy of moxibustion and acupuncture therapy for ankylosing spondylitis: A protocol for an overview of systematic reviews and meta-analysis

Background:Ankylosing spondylitis is a complex and progressive autoimmune inflammatory disease with a worldwide prevalence ranging up to 0.9%. Several systematic reviews and meta-analyses of traditional Chinese medicine alternative therapies, such as acupuncture or moxibustion, have demonstrated the effectiveness of moxibustion and acupuncture in the treatment of ankylosing spondylitis. However, there is no relevant literature to comprehensively evaluate the evidence. The purpose of this overview is to synthesize and evaluate the reliability of evidence generated in the systematic review (SR) and meta-analysis of moxibustion and acupuncture as a primary or complementary therapy for patients with ankylosing spondylitis.Methods:PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, Chinese VIP Information, Wanfang Database, and Chinese Biomedical Literature Database were searched for systematic reviews and meta-analysis that review the efficacy of acupuncture or moxibustion as the primary treatment for patients with Ankylosing Spondylitis. The literature published before August 2020 will be selected. Additionally, the relevant SRs and meta-analyses that unpublished or ongoing will be searched in PROSPERO and INPLASY. The methodological guidelines for overviews will be used to review and extract data by 2 reviewers, and their will do it independently. Methodology quality will be analyzed by the assessment of multiple systematic reviews-2and the risk of bias by POBIS. For the included studies, we will adopt the following results as primary evaluation indicators: effective rate, visual analogue scale and bath AS disease activity index. Reviewers will assess the certainty of evidence by Grading of Recommendations Assessment, Development and Evaluation.Results:The results will be published in a peer-reviewed journal.Conclusion:This overview will provide comprehensive evidence of moxibustion and acupuncture for patients with Ankylosing Spondylitis.     

Efficacy of warming needle moxibustion in the treatment of ankylosing spondylitis: A protocol of a randomized controlled trial

Background:Ankylosing spondylitis is a recurrent autoimmune disease, which has a high disability rate and seriously affects patients’ daily life. Conventional treatment cannot effectively solve the clinical problems of patients, and long-term medication is accompanied by adverse reactions. The evidence shows that warming needle moxibustion has advantages in the treatment of ankylosing spondylitis, but there is still a lack of clinical studies on warm acupuncture alone and long-term follow-up.Methods:This is a prospective randomized controlled trial to study the efficacy and safety of needle warming through moxibustion in the treatment of ankylosing spondylitis. It was approved by the Ethics Committee of Clinical Research of our hospital. Patients were randomly assigned to an observation group or a control group. The patients were followed up for 6 months after 30 days of treatment. Observation indicators include; activity index, functional ability, Bath Ankylosing Spondylitis Metrology Index, inflammatory indicators, adverse reactions, and so on. Finally, SPASS 22.0 software is used for statistical analysis of the data.Discussion:This study will evaluate the clinical efficacy of warming needle moxibustion in the treatment of ankylosing spondylitis. The results of this study will provide a reference basis for the clinical use of warm needle moxibustion in the treatment of ankylosing spondylitis.Trial registration:OSF Registration number: DOI 10.17605/OSF.IO/GWPX3     

Effectiveness of Exercise Programs in Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials

Objective

To assess the effectiveness of exercise programs on disease activity and function in ankylosing spondylitis (AS) by a systematic review and meta-analysis of randomized controlled trials (RCTs).

Higher frequency of peripheral blood follicular regulatory T cells in patients with new onset ankylosing spondylitis

Follicular helper T (TFH) cells and B cells are linked to the pathogenesis of ankylosing spondylitis (AS). Follicular regulatory T (TFR) cells suppress TFH cell and germinal center B cell numbers in vivo. The role of TFR cells in AS is unknown. The frequency of peripheral blood inducible FOXP3+CXCR5+CD4+TFR cells and CXCR5+CD4+TFH cells were taken from 20 onset AS patients and 10 healthy controls, and were examined by flow cytometry, their disease activity were measured by the Bath Ankylosing Spondylitis Disease Activity Index. The concentrations of serum interleukin (IL)‐21, immunoglobulin G, immunoglobulin A, immunoglobulin M and C‐reactive protein were examined, and the values of erythrocyte sedimentation rate were measured. The frequency of peripheral blood FOXP3+CXCR5+CD4+TFR cells, CXCR5+CD4+TFH cells, the ratio of FOXP3+CXCR5+CD4+TFR/CXCR5+CD4+TFH cells and the concentration of serum IL‐21 in the AS patients were significantly higher than those in the healthy controls (P < 0.0001, P = 0.0027, P < 0.0001, P = 0.0039, respectively). The frequency of FOXP3+CXCR5+CD4+TFR cells and the ratio of FOXP3+CXCR5+CD4+TFR/CXCR5+CD4+TFH cells still significantly rose in those patients after standard treatment (P = 0.0006, P < 0.0001), the concentration of serum IL‐21 decreased after treatment (P = 0.0049), accompanied by significantly minimized disease activities. Furthermore, the TFR cells were negatively correlated with serum immunoglobulin A in those patients before treatment (r = ?0.582, P = 0.0071), and the frequency of TFR cells was negatively correlated with that of TFH cells and the concentration of serum IL‐21 after treatment (r = ?0.550, P = 0.046; r = ?0.581, P = 0.0371). TFR cells might participate in the pathogenesis of AS, and might be responsible for controlling the autoantibodies, the frequency and function of TFH cells to inhibit the development of AS.     

甲氨蝶呤治疗强直性脊柱炎髋关节病变的临床研究

目的观察甲氨蝶呤（MTX）对强直性脊柱炎（AS）髋关节病变的临床疗效，并以柳氮磺吡啶（SSZ）作为对照，以评价MTX对AS髋关节病变的有效性及安全性。方法从住院的AS髋关节病变患者中随机选择MTX治疗的48例为观察组，并以年龄、性别、病程及病情相匹配，采用SSZ治疗的50例作为对照组，两组患者均选择一种非甾体抗炎药作为基础疗法。出院后继续原药物治疗，并随访3年的临床资料，包括临床症状、Bath AS活动指数（BASDAI）、Bath AS功能指数（BASFI）、髋关节功能评分、髋关节病变CT分期、炎性指标等实验室检查及不良反应。结果观察组第1、2、3年随访44、38、32例。对照组分别为45、38、31例。随访3年内，髋关节功能评分观察组显著高于对照组（P〈0．05）。髋关节CTI期病变，两组患者随访第2、3年与入院时比较明显减少（P〈0．05）；随访第2、3年，观察组比对照组显著下降（P〈0．05）。髋关节CTⅡ期病变，两组间各时段比较差异均无统计学意义。腰痛、腰背晨僵、BASDAI和BASFI、红细胞沉降率（ESR）、C反应蛋白（CRP），两组间对比差异均无统计学意义。不良反应以胃肠道反应为主．两组比较差异无统计学意义；随访所有病例无造血系统障碍发生。结论MTX对AS髋关节病变的疗效优于SSZ，在治疗3年内髋关节功能明显改善；MTX不良反应较轻，可作为治疗AS髋关节病变的首选药物，其更长期的疗效及安全性有待进一步观察。     

基质金属蛋白酶-3与强直性脊柱炎疾病活动相关性研究

目的本试验拟通过检测强直性脊柱炎(AS)患者血清和关节液中基质金属蛋白酶(MMP)-3的表达水平及分析其与AS病人疾病活动的相关性来确证和探讨MMP-3在AS发病中的作用。方法应用酶联免疫吸附试验(ELISA)检测两组AS患者血清中MMP-3的表达水平,一组是41例未用任何抗肿瘤坏死因子(TNF)-琢等生物制剂治疗的AS患者血清,另一组是13例应用抗TNF-琢单克隆抗体Infliximab治疗前和治疗14周后的AS患者血清,同时对比检测了28名正常对照个体血清和8例AS患者关节液中MMP-3的水平。结果AS患者关节液中MMP-3水平显著高于AS患者外周血水平(P<0.00001);41例未用任何生物制剂治疗的AS患者,其血清MMP-3的水平与AS疾病活动指数(BASDAI)(r=0.48,P=0.0007)和血沉(ESR)(r=0.54,P=0.0001)具有明显相关性;同时应用对数相关分析发现根据BASDAI值判别的病情活动度与ESR(P=0.025)和MMP-3(P=0.04)水平之间亦具有高度相关性。应用Infliximab治疗14周后,AS患者血清MMP-3水平和BASDAI值比治疗前显著下降(P=0.013和P=0.00007)。结论AS患者血清中MMP-3水平可作为评价AS疾病活动性潜在的生物学标志物。此外,由于MMP-3在关节和外周血中均有稳定水平的表达,因此MMP-3还是研究AS发病机制的肯定和有用候选基因。     

强直性脊柱炎髋关节异常的CT检查

目的：总结分析强直性脊柱炎(AS)髋关节异常在CT上的表现特点。方法：对21例有髋部症状的As病人进行了髋关节CT轴位3mm层厚连续扫描。结果:全部病例都出现髋关节间隙变窄，按放射学指数(BASR)-hip分级，69％(29／42)的关节有3、4级的较严重改变；其他改变有关节软骨下囊性变(90.5％)，股骨颈特征性的“衣领样”骨质增生改变、骨质疏松、关节囊肿胀等。结论:AS的髋关节异常在CT上有一定的特征性表现，结合同时有骶髂关节改变，可取得正确诊断。